See all treatments in the PatientsLikeMe system shared by patients just like you.
Brand Names:
Truvada
What is Emtricitabine-Tenofovir? Emtricitabine and tenofovir is an antiviral medication that prevents human immunodeficiency virus (HIV) from reproducing in your body. Emtricitabine and tenofovir treats HIV, which causes acquired immunodeficiency syndrome (AIDS).
See more information, including instructions, precautions, side effects, and interactions.
270 patients in the community are taking or have taken Emtricitabine-Tenofovir.
| Reason | # Patients | Percentage of patients |
|---|---|---|
| Treat my HIV | 189 | 70% |
| Other | 7 | 2% |
| Improve immune function | 3 | 1% |
| Support another treatment | 2 | <1% |
| Don't know | 2 | <1% |
| Fatigue | 1 | <1% |
| Anxiety | 1 | <1% |
| disease-related symptoms | 1 | <1% |
| General health | 1 | <1% |
Other treatments patients are taking for Treat my HIV include Efavirenz-Emtricitabine-Tenofovir, Ritonavir, and Atazanavir.
Based on the patients currently taking Emtricitabine-Tenofovir.
Top 10 (Show all)
All (Show top 10)
How long current patients have been taking Emtricitabine-Tenofovir or how long patients were taking Emtricitabine-Tenofovir before stopping.
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Doctor's advice | 11 | 42% | |
| Other | 9 | 35% | |
| Side effects too severe | 4 | 15% | |
| Expense | 3 | 12% | |
| Course of treatment ended | 2 | 8% | |
| Not indicated | 1 | 4% | |
| Personal research | 1 | 4% | |
| Did not seem to work | 1 | 4% |
Results from 24 patient evaluations. See the overall results and all individual evaluations.
| Major | 78% | 18 |
|---|---|---|
| Moderate | 9% | 2 |
| Can't tell | 13% | 3 |
Treat my HIV
| Severe | 4% | 1 |
|---|---|---|
| Moderate | 25% | 6 |
| Mild | 25% | 6 |
| None | 46% | 11 |
Top reported side-effects include: Diarrhea, lack of energy, Headaches
Summary results are based on 24 individual responses. For more information, see overall results for Adherence, Burden and Cost.
Report created on November 07, 2009.